Dr. Reddy's Laboratories Limited

NYSE:RDY Stock Report

Market Cap: US$13.2b

Dr. Reddy's Laboratories Future Growth

Future criteria checks 0/6

Dr. Reddy's Laboratories's earnings are forecast to decline at 1.2% per annum while its annual revenue is expected to grow at 4.9% per year. EPS is expected to decline by 2.2% per annum. Return on equity is forecast to be 14.7% in 3 years.

Key information

-1.2%

Earnings growth rate

-2.2%

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth rate4.9%
Future return on equity14.7%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

No updates

Recent updates

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Aug 13

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's: Growth Supported By New Labels, Profitability

Aug 23

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Jun 07

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Feb 16

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

Earnings and Revenue Growth Forecasts

NYSE:RDY - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2027341,22849,29053,84766,95034
3/31/2026346,58161,21752,36067,40938
3/31/2025321,19658,41518,98459,46137
9/30/2024299,86753,3328,83034,069N/A
6/30/2024288,50755,57921,01242,679N/A
3/31/2024279,16455,68418,01945,433N/A
12/31/2023271,30252,20628,71353,592N/A
9/30/2023266,85450,88849,17972,115N/A
6/30/2023261,10947,21641,12363,470N/A
3/31/2023245,87945,06740,00958,875N/A
12/31/2022237,27936,35029,17048,315N/A
9/30/2022222,77630,94421,86642,386N/A
6/30/2022217,35129,73616,75538,211N/A
3/31/2022214,39123,56812,00528,108N/A
12/31/2021207,30726,31714,97630,255N/A
9/30/2021203,40619,4501,59717,194N/A
6/30/2021194,74117,1537,33521,342N/A
3/31/2021189,72217,23823,14235,703N/A
12/31/2020186,75621,25615,52826,983N/A
9/30/2020181,29815,36122,02630,069N/A
6/30/2020180,34018,66324,35430,921N/A
3/31/2020174,60019,49823,98529,841N/A
12/31/2019170,44816,20028,93034,006N/A
9/30/2019165,11026,74937,51142,937N/A
6/30/2019155,07920,86237,40043,559N/A
3/31/2019153,85118,79521,21328,704N/A
12/31/2018149,03417,47319,95327,774N/A
9/30/2018148,59415,9659,57619,007N/A
6/30/2018145,90313,776N/A14,986N/A
3/31/2018141,8559,806N/A18,029N/A
12/31/2017141,8279,909N/A20,765N/A
9/30/2017140,58811,266N/A18,478N/A
6/30/2017140,90711,367N/A14,480N/A
3/31/2017139,87012,039N/A21,513N/A
12/31/2016141,2699,660N/A22,252N/A
9/30/2016144,12710,751N/A29,018N/A
6/30/2016148,41015,019N/A37,693N/A
3/31/2016153,86620,013N/A41,247N/A
12/31/2015155,85024,456N/A42,252N/A
9/30/2015154,60224,409N/A36,012N/A
6/30/2015150,59222,932N/A29,083N/A
3/31/2015147,36022,179N/A25,033N/A
12/31/2014143,47421,806N/A22,860N/A
9/30/2014140,38022,247N/A23,151N/A
6/30/2014138,07623,409N/A19,532N/A
3/31/2014132,17021,515N/A19,463N/A
12/31/2013130,04322,409N/A13,951N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDY's earnings are forecast to decline over the next 3 years (-1.2% per year).

Earnings vs Market: RDY's earnings are forecast to decline over the next 3 years (-1.2% per year).

High Growth Earnings: RDY's earnings are forecast to decline over the next 3 years.

Revenue vs Market: RDY's revenue (4.9% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: RDY's revenue (4.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RDY's Return on Equity is forecast to be low in 3 years time (14.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dr. Reddy's Laboratories Limited is covered by 77 analysts. 38 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited